Clinical Impact of Semaglutide, a Glucagon-Like Peptide-1 Receptor Agonist, on Obesity Management: A Review

Nasser M. Alorfi, Alanood Saeed Algarni
ISSN / E-ISSN
— / —
DOI
10.2147/cpaa.s374741 ↗
Volume · Issue · Pages
Volume 14 · — · 61-67
Publisher
Dove Medical Press Ltd.
Article URL
https://doi.org/10.2147/cpaa.s374741 ↗
Article details
Unverified
Publication date (each date has its type and source)
01 Aug 2022
OpenAlex publication date · source: OpenAlex
Dates on record for this article
TypeDateSource
OpenAlex publication date01 Aug 2022 OpenAlex

Keywords (as given): semaglutide; GLP-1 receptor agonists; obesity; weight loss; appetite suppression; pharmacokinetics; pharmacodynamics; adverse effects; gastrointestinal adverse effects; HbA1c; energy intake

HEC Status at Publication Not the journal's current status

HEC Status at PublicationConclusive
HEC status at publication Recognized Y
Based on the recorded HEC dataset applicable to the article's publication date. Listed as Y in the HEC list for 2022–23.
Journal
Clinical Pharmacology: Advances and Applications
Publication date used
01 Aug 2022 (OpenAlex publication date)
Applicable HEC period
2022–23 (version 2) · 01 Jul 2022 – 30 Jun 2023
Category
Y
Recognition status
Recognized (OK_RECORD_FOUND)
Source
hjrs-2022-23 row 17304
Verification status
Verified against source · last verified 16 Oct 2026
This is an automatically generated summary based on the information available on the publication date. Terms & conditions apply.